Sermorelin peptide.

Sermorelin stimulates growth-hormone release

Sermorelin is a 29-amino-acid peptide that signals the pituitary gland to release growth hormone. Its chemical name, GHRH(1–29)-NH₂, describes the active first 29 amino acids of growth hormone–releasing hormone, with an amide at the end. The supplied vial and pen contain sermorelin as their only active peptide. [1] [2]

The product is manufactured. “Stimulates your own growth hormone” describes its mechanism; it does not mean the injected peptide is extracted from a person. The short label GRF(1–29) also appears in product descriptions. Sermorelin acetate names a salt form used in clinical research; the supplied specifications do not establish the counterion of this particular lot. [1]

Body composition, workout recovery and sleep are the main reasons it is discussed. A useful comparison starts with the exact outcome: more lean tissue, less fat, better exercise performance or improved sleep. A higher hormone number alone does not tell you which of those changes occurred.

Sermorelin benefits: the measured changes

Six percent less body fat does not mean six percentage points lower body-fat percentage. For a purely numerical example, reducing 20 kg of fat by 6% removes 1.2 kg, leaving 18.8 kg. It does not mean losing 6% of total body weight. Changes in lean tissue also affect the final weight and percentage.

Strength and muscle size are separate measurements. A heavier shoulder press can improve without a measurable increase in muscle mass. Recovery also has several meanings: less soreness, better training performance and healing a diagnosed injury are different claims.

The sermorelin benefits article covers fat distribution, lean mass, sleep, cognition and differences between men and women. Each result stays attached to its actual study and treatment.

Growth hormone and IGF-1 measure different things

Growth hormone rises and falls throughout the day. IGF-1 is more stable. That makes IGF-1 useful when assessing the GH system. A low result can reflect age or another condition, and further testing may be needed to establish a diagnosis. [3]

A lab change is evidence of a hormone response. It is not a substitute for a body-composition measurement, a sleep assessment or a strength result. Conversely, a better workout after changing your training does not establish how much a peptide contributed.

For example, an IGF-1 increase from 150 to 200 ng/mL is a 50 ng/mL increase, or 33.3%. That arithmetic does not mean 33.3% more muscle, 33.3% better sleep or a 33.3% reduction in fat. Percentages belong to the variable that was measured.

The results article separates lab values, measured body changes and individual experiences, including outcomes that did not improve.

Daily dosage and syringe units

300 mcg nightly, five days on and two days off, appears in a documented adult prescription account. That is one prescribed schedule, not a dose-finding trial or a universal starting amount. [7]

A 10 mg vial at 2 mL final volume contains 5 mg/mL. At that concentration, 300 mcg equals 0.06 mL, or six units on a U-100 syringe. At 3 mL final volume, the same 300 mcg requires 0.09 mL, or nine units. Adding more liquid changes the draw volume, not the amount of peptide in the vial.

The sermorelin calculator starts with your target amount, then uses the vial total and final mixed volume to show mL and U-100 units. The syringe marker moves with the result. The loaded 300 mcg value demonstrates conversion; it does not select a treatment amount.

U-100 units measure volume here. One unit equals 0.01 mL. They are not international units of growth-hormone activity, and they cannot be copied onto an unverified pen dial. A number such as “six units” is incomplete without the concentration and device scale.

Reconstitution graphics, general subcutaneous sites, bedtime and food questions, and the full calculation tool appear on the dosage and cycles page.

Cycle length and total supply

Frequency changes how much material a course uses. At 300 mcg per administration, five active days total 1.5 mg each week. Seven active days total 2.1 mg. The seven-day schedule uses 40% more material over the same number of calendar weeks.

These are purchasing calculations, not recommended cycle lengths. A calendar duration, an assessment date and a container's permitted use period are different limits. Buying enough milligrams for twelve weeks does not establish that one prepared container can remain in use for twelve weeks.

A 10 mg vial holds 33 full 300 mcg portions, with 100 mcg left, before losses. A 6 mg pen holds twenty theoretical portions of the same amount. Priming, transfer losses and discard limits reduce usable yield.

The course-quantity table converts those totals into whole vials and pens. The earlier cycle section compares actual treatment durations and separates them from unsupported claims about mandatory breaks.

10 mg vial and 6 mg pen

The vial contains 10 mg of powder. The pen contains 6 mg in 3 mL of prepared solution. The pen's concentration is 2 mg/mL, so it is less concentrated than a 10 mg vial prepared to a final volume of 2 mL. [1]

Research-labelled products. Drawings show the formats; they are not product photographs.

Vial: concentration depends on the final mixed volume. The documented handling calls for slow addition of the method-specified diluent against the glass wall, without shaking. The specifications do not establish one universal diluent or post-mixing expiry.

Pen: already mixed, with water and 0.9% benzyl alcohol. Do not add water to the cartridge. At its stated 2 mg/mL concentration, 300 mcg corresponds to 0.15 mL. The product-specific dial and mechanical-click calibration have not been supplied, so that volume cannot yet be translated into a verified pen setting. [1]

Storage differs before preparation. The sealed powder specifies −20°C, dry and protected from light. Prepared vial solution specifies 2–8°C. The pen also specifies 2–8°C, protection from light and no freezing. Keep the original container's instructions with the product rather than applying one format's storage rule to the other.

The buying page compares ingredient quantities, preparation, storage and certificate coverage side by side.

Sermorelin, HGH, tesamorelin and ipamorelin

HGH replacement supplies the hormone itself. Tesamorelin and sermorelin are different molecules despite both being related to GHRH. Ipamorelin was characterised through a different receptor pathway in preclinical research. [3] [8] [9]

A combination changes the ingredient list. A vial labelled “sermorelin + ipamorelin” cannot use a single-ingredient sermorelin total without checking the split. If a hypothetical blend contains 5 mg of each ingredient, its 10 mg total contains only 5 mg sermorelin. The two products compared here contain sermorelin as their only active peptide.

See the separate tesamorelin peptide guide for that compound's clinical results and product calculations. Matching vial sizes do not make the compounds interchangeable.

Flushing, nausea and injection reactions

Those examples come from different settings and do not supply a single side-effect rate for the current vial or pen. The pen also contains benzyl alcohol, which is separate from the peptide ingredient. Product ingredients belong in any assessment of a reaction. [1]

The side-effects article covers local reactions, hormone and glucose questions, thyroid medication, pregnancy, cancer history and symptoms that require prompt assessment. It distinguishes adverse effects recorded in human studies from risks inferred from the wider GH pathway.

Redacted COA: lot PL-2609-098

The attached certificate covers sampled 10 mg powder vials. It records LC-MS identity at 3358.1 Da, endotoxin at 0.05 EU/mg and no growth after fourteen days in the sterility test. Two vials were sampled from a 250-unit lot. [10]

The purity figures need clarification. The report states 99.63% HPLC area purity, but its printed peak areas calculate to 99.48%. The listed percentages also total 100.15%. The analytical data is preserved in the redacted copy, with this discrepancy shown beside it.

HPLC area purity is not an assay of the exact milligrams in every vial. The powder report also does not establish the content or sterility of the finished pen, or link a specific pen batch to the sampled powder. Open the redacted two-page certificate and test summary for the full figures and report scope.